Stenzl - Figure 26
Overall Survival According to Molecular Subtype
FIG. 26: Importantly, these different tumors fare differently with respect to response to neoadjuvant chemotherapy when the TURB specimen is compared with the cystectomy specimen.[19] For example, in the UNC classification,[4] basal tumors respond well to neoadjuvant chemotherapy, as well as cluster III tumors in the TCGA classification.[2] But when infiltrative and Uro B tumors are classified according to the Lund classification,[3] there is a significant change between the primary TURB and the cystectomy specimen if neoadjuvant chemotherapy was applied.
References
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014:507:315−22 nature.com/doifinder/10.1038/nature12965
Sjödahl G, Lauss M, Lövgren K, Chebil G, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18:3377−86 https://doi.org/10.1158/1078-0432.CCR-12-0077-T
Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;25:3110–5 https://doi.org/10.1073/pnas.1318376111
Seiler R, Ashab HA, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. Published online April 5, 2017 http://dx.doi.org/10.1016/j.eururo.2017.03.030